Can iPCSK9-induced hypocholesterolemia starve cancer cells?

J Clin Lipidol. 2017 May-Jun;11(3):600-601. doi: 10.1016/j.jacl.2017.04.001. Epub 2017 Apr 21.

Authors

Anne Gangloff¹, Frédéric Calon², Nabil G Seidah³

Affiliations

¹ Lipid Clinic, CHU de Québec, Québec, Canada; Endocrinology and Nephrology Research Axis, CHU de Québec, Québec, Canada. Electronic address: anne.gangloff.1@ulaval.ca.
² Faculty of Pharmacy, Laval University, Québec, Québec, Canada; Neuroscience Research Axis, CHU de Québec, Québec, Canada.
³ Laboratory of Biochemical Neuroendocrinology, Institut de Recherches Cliniques de Montréal, Québec, Canada.

PMID: 28506383
DOI: 10.1016/j.jacl.2017.04.001

No abstract available

Publication types

Editorial

MeSH terms

Cell Proliferation / drug effects
Cholesterol / metabolism*
Humans
Neoplasms / metabolism*
Neoplasms / pathology*
PCSK9 Inhibitors*
Serine Proteinase Inhibitors / pharmacology*

Substances

PCSK9 Inhibitors
Serine Proteinase Inhibitors
Cholesterol